<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39028694</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>30</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response.</ArticleTitle><Pagination><StartPage>e2408109121</StartPage><MedlinePgn>e2408109121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2408109121</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2408109121</ELocationID><Abstract><AbstractText>The prevalence of "long COVID" is just one of the conundrums highlighting how little we know about the lung's response to viral infection, particularly to syndromecoronavirus-2 (SARS-CoV-2), for which the lung is the point of entry. We used an in vitro human lung system to enable a prospective, unbiased, sequential single-cell level analysis of pulmonary cell responses to infection by multiple SARS-CoV-2 strains. Starting with human induced pluripotent stem cells and emulating lung organogenesis, we generated and infected three-dimensional, multi-cell-type-containing lung organoids (LOs) and gained several unexpected insights. First, SARS-CoV-2 tropism is much broader than previously believed: Many lung cell types are infectable, if not through a canonical receptor-mediated route (e.g., via Angiotensin-converting encyme 2(ACE2)) then via a noncanonical "backdoor" route (via macropinocytosis, a form of endocytosis). Food and Drug Administration (FDA)-approved endocytosis blockers can abrogate such entry, suggesting adjunctive therapies. Regardless of the route of entry, the virus triggers a lung-autonomous, pulmonary epithelial cell-intrinsic, innate immune response involving interferons and cytokine/chemokine production in the absence of hematopoietic derivatives. The virus can spread rapidly throughout human LOs resulting in mitochondrial apoptosis mediated by the prosurvival protein Bcl-xL. This host cytopathic response to the virus may help explain persistent inflammatory signatures in a dysfunctional pulmonary environment of long COVID. The host response to the virus is, in significant part, dependent on pulmonary Surfactant Protein-B, which plays an unanticipated role in signal transduction, viral resistance, dampening of systemic inflammatory cytokine production, and minimizing apoptosis. Exogenous surfactant, in fact, can be broadly therapeutic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leibel</LastName><ForeName>Sandra L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McVicar</LastName><ForeName>Rachael N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murad</LastName><ForeName>Rabi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Alex E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0003-1687-416X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarado</LastName><ForeName>Asuka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmig</LastName><ForeName>Bethany A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuryyev</LastName><ForeName>Ruslan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Randee E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jamie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Weiqi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yanfang P</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffis</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nikon Imaging Center, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowell</LastName><ForeName>Cameron J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-8662-9840</Identifier><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alarcon</LastName><ForeName>Suzie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>La Jolla Institute for Immunology, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Atul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Linden J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Translational Sciences, Monash University Clayton, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hertzog</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Translational Sciences, Monash University Clayton, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galapate</LastName><ForeName>Cheska M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute Cell &amp; Molecular Biology of Cancer, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galenkamp</LastName><ForeName>Koen M O</ForeName><Initials>KMO</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Commisso</LastName><ForeName>Cosimo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute Cell &amp; Molecular Biology of Cancer, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Davey M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlin</LastName><ForeName>Aaron F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidman</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Croker</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Snyder</LastName><ForeName>Evan Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, Center for Stem Cells &amp; Regenerative Medicine, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL157985</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA207189</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DISC2COVID19-12022</GrantID><Agency>California Institute for Regenerative Medicine (CIRM)</Agency><Country/></Grant><Grant><GrantID>T32 HL166127</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI036214</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>S10 OD026929</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI036214</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3R01CA207189-05S1</GrantID><Agency>HHS | NIH | National Cancer Institute (NCI)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="Y">Virus Internalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="Y">Organoids</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">lung organoids</Keyword><Keyword MajorTopicYN="N">macropinocytosis</Keyword><Keyword MajorTopicYN="N">surfactant</Keyword></KeywordList><CoiStatement>Competing interests statement:C.C. is an inventor on a patent titled &#x2018;&#x2018;Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis,&#x2019;&#x2019; Pub. No.: US 2018/0335420 A1.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39028694</ArticleId><ArticleId IdType="pmc">PMC11287264</ArticleId><ArticleId IdType="doi">10.1073/pnas.2408109121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wendisch D., et al. , SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell 184, 6243&#x2013;6261.e27 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626230</ArticleId><ArticleId IdType="pubmed">34914922</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G. U., et al. , Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107, 1062&#x2013;1073 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7705118</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavan M., Bassani D., Sturlese M., Moro S., From the Wuhan-Hu-1 strain to the XD and XE variants: Is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? J. Enzyme Inhib. Med. Chem. 37, 1704&#x2013;1714 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9196651</ArticleId><ArticleId IdType="pubmed">35695095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriatopoulou M., et al. , Emerging treatment strategies for COVID-19 infection. Clin. Exp. Med. 21, 167&#x2013;179 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598940</ArticleId><ArticleId IdType="pubmed">33128197</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder J., Minko T., Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 23, 14 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784226</ArticleId><ArticleId IdType="pubmed">33400058</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., McVicar R. N., Winquist A. M., Niles W. D., Snyder E. Y., Generation of complete multi-cell type lung organoids from human embryonic and patient-specific induced pluripotent stem cells for infectious disease modeling and therapeutics validation. Curr. Protoc. Stem Cell Biol. 54, e118 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361156</ArticleId><ArticleId IdType="pubmed">32640120</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., et al. , Reversal of surfactant protein B deficiency in patient specific human induced pluripotent stem cell derived lung organoids by gene therapy. Sci. Rep. 9, 13450 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748939</ArticleId><ArticleId IdType="pubmed">31530844</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y., et al. , Long-term expansion of alveolar stem cells derived from human iPS cells in organoids. Nat. Methods 14, 1097&#x2013;1106 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28967890</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley K. B., Hawkins F., Kotton D. N., Derivation of epithelial-only airway organoids from human pluripotent stem cells. Curr. Protoc. Stem Cell Biol. 45, e51 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060639</ArticleId><ArticleId IdType="pubmed">30040246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiege J. K., et al. , Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. PLoS Pathog. 17, e1009292 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7872261</ArticleId><ArticleId IdType="pubmed">33507952</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason R. J., Pathogenesis of COVID-19 from a cell biology perspective. Eur. Respir. J. 55, 2000607 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144260</ArticleId><ArticleId IdType="pubmed">32269085</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua R. L., et al. , COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. 38, 970&#x2013;979 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32591762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindra N. G., et al. , Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. PLoS Biol. 19, e3001143 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007021</ArticleId><ArticleId IdType="pubmed">33730024</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorey T. M., et al. , COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 595, 107&#x2013;113 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919505</ArticleId><ArticleId IdType="pubmed">33915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms J. C., et al. , A molecular single-cell lung atlas of lethal COVID-19. Nature 595, 114&#x2013;119 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>Milross L., et al. , Post-mortem lung tissue: The fossil record of the pathophysiology and immunopathology of severe COVID-19. The Lancet Respir. Med. 10, 95&#x2013;106 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8641959</ArticleId><ArticleId IdType="pubmed">34871544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauad T., et al. , Tracking the time course of pathological patterns of lung injury in severe COVID-19. Respir Res. 22, 32 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844838</ArticleId><ArticleId IdType="pubmed">33514373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagno V., SARS-CoV-2 cellular tropism. The Lancet Microbe 1, e2&#x2013;e3 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7173832</ArticleId><ArticleId IdType="pubmed">32835319</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., et al. , Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells. Immun. Inflamm. Dis. 8, 753&#x2013;762 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654422</ArticleId><ArticleId IdType="pubmed">33124193</ArticleId></ArticleIdList></Reference><Reference><Citation>Travaglini K. J., et al. , A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature 587, 619&#x2013;625 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704697</ArticleId><ArticleId IdType="pubmed">33208946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley K., et al. , Reconstructed single-cell fate trajectories define lineage plasticity windows during differentiation of human PSC-derived distal lung progenitors. Cell Stem Cell 26, 593&#x2013;608.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7469703</ArticleId><ArticleId IdType="pubmed">32004478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardini-Poleske M. E., et al. , LungMAP: The molecular atlas of lung development program. Am. J. Physiol. Lung Cell Mol. Physiol. 313, L733&#x2013;L740 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792185</ArticleId><ArticleId IdType="pubmed">28798251</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y., Guo M., Whitsett J. A., Xu Y., &#x201c;LungGENS&#x201d;: A web-based tool for mapping single-cell gene expression in the developing lung. Thorax 70, 1092&#x2013;1094 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641439</ArticleId><ArticleId IdType="pubmed">26130332</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyfman P. A., et al. , Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 199, 1517&#x2013;1536 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580683</ArticleId><ArticleId IdType="pubmed">30554520</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller H. B., et al. , The human lung cell atlas: A high-resolution reference map of the human lung in health and disease. Am. J. Respir. Cell Mol. Biol. 61, 31&#x2013;41 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6604220</ArticleId><ArticleId IdType="pubmed">30995076</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., et al. , Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. JCI Insight 1, e90558 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135277</ArticleId><ArticleId IdType="pubmed">27942595</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley K. B., et al. , Single-cell transcriptomic profiling of pluripotent stem cell-derived SCGB3A2+ airway epithelium. Stem Cell Rep. 10, 1579&#x2013;1595 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5995784</ArticleId><ArticleId IdType="pubmed">29657097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., et al. , Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva L., et al. , Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603405</ArticleId><ArticleId IdType="pubmed">32707573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunnari G., et al. , Network perturbation analysis in human bronchial epithelial cells following SARS-CoV2 infection. Exp. Cell Res. 395, 112204 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386311</ArticleId><ArticleId IdType="pubmed">32735892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota C., et al. , Dynamic expression of HOPX in alveolar epithelial cells reflects injury and repair during the progression of pulmonary fibrosis. Sci. Rep. 8, 12983 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113210</ArticleId><ArticleId IdType="pubmed">30154568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., et al. , Single-cell analysis identified lung progenitor cells in COVID-19 patients. Cell Prolif. 53, e12931 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645905</ArticleId><ArticleId IdType="pubmed">33094537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunigan K., et al. , The thioredoxin reductase inhibitor auranofin induces heme oxygenase-1 in lung epithelial cells via Nrf2-dependent mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol. 315, L545&#x2013;L552 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6230877</ArticleId><ArticleId IdType="pubmed">30024305</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., et al. , The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Sci. Rep. 10, 16824 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544910</ArticleId><ArticleId IdType="pubmed">33033346</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Li L., Wang X., Identifying pathways and networks associated with the SARS-CoV-2 cell receptor ACE2 based on gene expression profiles in normal and SARS-CoV-2-infected human tissues. Front. Mol. Biosci. 7, 568954 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7597396</ArticleId><ArticleId IdType="pubmed">33195414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lissanu Deribe Y., et al. , Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat. Med. 24, 1047&#x2013;1057 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6650267</ArticleId><ArticleId IdType="pubmed">29892061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M., et al. , Respiratory syncytial virus co-opts host mitochondrial function to favour infectious virus production. eLife 8, e42448 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6598784</ArticleId><ArticleId IdType="pubmed">31246170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini R., Cecchini A. L., SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med. Hypotheses 143, 110102 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357498</ArticleId><ArticleId IdType="pubmed">32721799</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitnauer M., Mijo&#x161;ek V., Dalpke A. H., Control of local immunity by airway epithelial cells. Mucosal. Immunol. 9, 287&#x2013;298 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26627458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt R. J., Lloyd C. M., Regulation of immune responses by the airway epithelial cell landscape. Nat. Rev. Immunol. 21, 347&#x2013;362 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804588</ArticleId><ArticleId IdType="pubmed">33442032</ArticleId></ArticleIdList></Reference><Reference><Citation>Brune K., Frank J., Schwingshackl A., Finigan J., Sidhaye V. K., Pulmonary epithelial barrier function: Some new players and mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L731&#x2013;L745 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747906</ArticleId><ArticleId IdType="pubmed">25637609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., et al. , SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271&#x2013;280.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C. B., Farzan M., Chen B., Choe H., Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3&#x2013;20 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B., Zhang L., Liu H., Ma S., Mi K., The dynamic expression of potential mediators of severe acute respiratory syndrome coronavirus 2 cellular entry in fetal, neonatal, and adult rhesus monkeys. Front. Genet. 11, 607479 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848180</ArticleId><ArticleId IdType="pubmed">33537060</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad K., AlOmar S. Y., Almuqri E. A., Rudayni H. A., Kumar V., Genomics-guided identification of potential modulators of SARS-CoV-2 entry proteases, TMPRSS2 and Cathepsins B/L. PLoS One 16, e0256141 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8372896</ArticleId><ArticleId IdType="pubmed">34407143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M.-M., et al. , Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct. Target. Ther. 6, 134 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997800</ArticleId><ArticleId IdType="pubmed">33774649</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzikowska U., et al. , Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 75, 2829&#x2013;2845 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300910</ArticleId><ArticleId IdType="pubmed">32496587</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna S., et al. , PIKfyve regulates vacuole maturation and nutrient recovery following engulfment. Dev. Cell 38, 536&#x2013;547 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5046836</ArticleId><ArticleId IdType="pubmed">27623384</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P. T., Einav S., Asquith C. R. M., PIKfyve: A lipid kinase target for COVID-19, cancer and neurodegenerative disorders. Nat. Rev. Drug Discov. 20, 730 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166417</ArticleId><ArticleId IdType="pubmed">34504321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. Y., et al. , SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. J. Biol. Chem. 298, 102511 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484108</ArticleId><ArticleId IdType="pubmed">36259516</ArticleId></ArticleIdList></Reference><Reference><Citation>L. T. Duong, A. T. Leung, B. Langdahl, Cathepsin K inhibition: A new mechanism for the treatment of osteoporosis. Calcif. Tissue Int. 98, 381&#x2013;397 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26335104</ArticleId></ArticleIdList></Reference><Reference><Citation>I. Rusinova et al., Interferome v2.0: An updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040&#x2013;D1046 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531205</ArticleId><ArticleId IdType="pubmed">23203888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertzog P., Forster S., Samarajiwa S., Systems biology of interferon responses. J. Interferon Cytokine Res. 31, 5&#x2013;11 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21226606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xe4;mer A., Green J., Pollard J. Jr., Tugendreich S., Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523&#x2013;530 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928520</ArticleId><ArticleId IdType="pubmed">24336805</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass A., Liu Y., Dakshanamurthy S., Single-cell and bulk RNASeq profiling of COVID-19 patients reveal immune and inflammatory mechanisms of infection-induced organ damage. Viruses 13, 2418 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8706409</ArticleId><ArticleId IdType="pubmed">34960687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., et al. , A Novel Coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727&#x2013;733 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkovska A., Kolomaznik M., Calkovsky V., Alveolar type II cells and pulmonary surfactant in COVID-19 era. Physiol. Res. 70, S195&#x2013;S208 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8884364</ArticleId><ArticleId IdType="pubmed">34913352</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot L., et al. , Alveolar epithelial cells: Master regulators of lung homeostasis. Int. J. Biochem. Cell Biol. 45, 2568&#x2013;2573 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23988571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamvas A., et al. , Developmental and genetic regulation of human surfactant protein B in vivo. Neonatology 95, 117&#x2013;124 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765709</ArticleId><ArticleId IdType="pubmed">18776725</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttentag S., Posttranslational regulation of surfactant protein B expression. Semin. Perinatol. 32, 367&#x2013;370 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586979</ArticleId><ArticleId IdType="pubmed">18929160</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter S., Moser C., Baack M., Respiratory distress in the newborn. Pediatr. Rev. 35, 417&#x2013;428 (2014), quiz 429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4533247</ArticleId><ArticleId IdType="pubmed">25274969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavvadia V., Greenough A., Itakura Y., Dimitriou G., Neonatal lung function in very immature infants with and without RDS. J. Perinat. Med. 27, 382&#x2013;387 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10642959</ArticleId></ArticleIdList></Reference><Reference><Citation>de Winter J. P., Merth I. T., Brand R., Quanjer P. H., Functional residual capacity and static compliance during the first year in preterm infants treated with surfactant. Am. J. Perinatol. 17, 377&#x2013;384 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">12141525</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson J., Curstedt T., Synthetic surfactants with SP-B and SP-C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases. J. Intern. Med. 285, 165&#x2013;186 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30357986</ArticleId></ArticleIdList></Reference><Reference><Citation>Schousboe P., et al. , Assessment of pulmonary surfactant in COVID-19 patients. Crit. Care 24, 552 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7475719</ArticleId><ArticleId IdType="pubmed">32894160</ArticleId></ArticleIdList></Reference><Reference><Citation>Sever N., Mili&#x10d;i&#x107; G., Bodnar N. O., Wu X., Rapoport T. A., Mechanism of lamellar body formation by lung surfactant protein B. Mol. Cell 81, 49&#x2013;66.e48 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797001</ArticleId><ArticleId IdType="pubmed">33242393</ArticleId></ArticleIdList></Reference><Reference><Citation>Osanai K., Mizuno S., Toga H., Takahashi K., Trafficking of newly synthesized surfactant protein B to the lamellar body in alveolar type II cells. Cell Tissue Res. 381, 427&#x2013;438 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32556725</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster C. D., Zhang P. X., Gonzales L. W., Guttentag S. H., In vitro surfactant protein B deficiency inhibits lamellar body formation. Am. J. Respir. Cell Mol. Biol. 29, 259&#x2013;266 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12649122</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson A. L., et al. , Post-translational processing of surfactant protein-C proprotein. Am. J. Respir. Cell Mol. Biol. 24, 253&#x2013;263 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11245624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamvas A., Nogee L. M., deMello D. E., Cole F. S., Pathophysiology and treatment of surfactant protein-B deficiency. Biol. Neonate 67 (suppl. 1), 18&#x2013;31 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7647155</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttentag S. H., Beers M. F., Bieler B. M., Ballard P. L., Surfactant protein B processing in human fetal lung. Am. J. Physiol. 275, L559&#x2013;L566 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9728051</ArticleId></ArticleIdList></Reference><Reference><Citation>Coya J. M., et al. , Natural anti-infective pulmonary proteins. In vivo cooperative action of surfactant protein SP-A and the lung antimicrobial peptide SP-BN. J. Immunol. 195, 1628&#x2013;1636 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530084</ArticleId><ArticleId IdType="pubmed">26163587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegami M., Whitsett J. A., Martis P. C., Weaver T. E., Reversibility of lung inflammation caused by SP-B deficiency. Am. J. Physiol. Lung Cell Mol. Physiol. 289, L962&#x2013;L970 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16024721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., et al. , Surfactant protein B propeptide contains a saposin-like protein domain with antimicrobial activity at low pH. J. Immunol. 184, 975&#x2013;983 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803329</ArticleId><ArticleId IdType="pubmed">20007532</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogee L. M., et al. , A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J. Clin. Invest. 93, 1860&#x2013;1863 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC294267</ArticleId><ArticleId IdType="pubmed">8163685</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogee L. M., Wert S. E., Proffit S. A., Hull W. M., Whitsett J. A., Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am. J. Respir. Crit. Care Med. 161, 973&#x2013;981 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10712351</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob A., et al. , Differentiation of human pluripotent stem cells into functional lung alveolar epithelial cells. Cell Stem Cell 21, 472&#x2013;488.e10 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5755620</ArticleId><ArticleId IdType="pubmed">28965766</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil B. A., Elemam N. M., Maghazachi A. A., Chemokines and chemokine receptors during COVID-19 infection. Comput. Struct. Biotechnol. J. 19, 976&#x2013;988 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859556</ArticleId><ArticleId IdType="pubmed">33558827</ArticleId></ArticleIdList></Reference><Reference><Citation>Inde Z., et al. , Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity. Sci. Adv. 7, eabf8609 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373124</ArticleId><ArticleId IdType="pubmed">34407940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan R., Bhatia J. J., Sekar K., Ernst F. R., Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: A retrospective study. J. Perinatol. 33, 119&#x2013;125 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558698</ArticleId><ArticleId IdType="pubmed">21886094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright J. R., Pulmonary surfactant: A front line of lung host defense. J. Clin. Invest. 111, 1453&#x2013;1455 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155177</ArticleId><ArticleId IdType="pubmed">12750392</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright J. R., Immunomodulatory functions of surfactant. Physiol. Rev. 77, 931&#x2013;962 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9354809</ArticleId></ArticleIdList></Reference><Reference><Citation>Numata M., Chu H. W., Dakhama A., Voelker D. R., Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc. Natl. Acad. Sci. U.S.A. 107, 320&#x2013;325 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806703</ArticleId><ArticleId IdType="pubmed">20080799</ArticleId></ArticleIdList></Reference><Reference><Citation>Spragg R. G., et al. , Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. 351, 884&#x2013;892 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15329426</ArticleId></ArticleIdList></Reference><Reference><Citation>Voelker D. R., Numata M., Phospholipid regulation of innate immunity and respiratory viral infection. J. Biol. Chem. 294, 4282&#x2013;4289 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433062</ArticleId><ArticleId IdType="pubmed">30733339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirastschijski U., Dembinski R., Maedler K., Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia. Front. Med. (Lausanne) 7, 254 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256165</ArticleId><ArticleId IdType="pubmed">32574339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., et al. , The role of pulmonary surfactants in the treatment of acute respiratory distress syndrome in COVID-19. Front. Pharmacol. 12, 698905 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276044</ArticleId><ArticleId IdType="pubmed">34267664</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramod K., et al. , Surfactant-based prophylaxis and therapy against COVID-19: A possibility. Med Hypotheses 143, 110081&#x2013;110081 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340033</ArticleId><ArticleId IdType="pubmed">32653736</ArticleId></ArticleIdList></Reference><Reference><Citation>Dessie Z. G., Zewotir T., Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 21, 855 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380115</ArticleId><ArticleId IdType="pubmed">34418980</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb Hooper M., N&#xe1;poles A. M., P&#xe9;rez-Stable E. J., COVID-19 and racial/ethnic disparities. Jama 323, 2466&#x2013;2467 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9310097</ArticleId><ArticleId IdType="pubmed">32391864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A., et al. , Single-cell multiomic profiling of human lungs reveals cell-type-specific and age-dynamic control of SARS-CoV2 host genes. Elife 9, e62522 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688309</ArticleId><ArticleId IdType="pubmed">33164753</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., et al. , A therapy for suppressing canonical and non-canonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response. NCBI Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214762. Deposited 27 September 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11287264</ArticleId><ArticleId IdType="pubmed">39028694</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., et al. , A therapy for suppressing canonical and non-canonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response. NCBI Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214752. Deposited 27 September 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11287264</ArticleId><ArticleId IdType="pubmed">39028694</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., et al. , A therapy for suppressing canonical and non-canonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response. NCBI Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214770. Deposited 27 September 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11287264</ArticleId><ArticleId IdType="pubmed">39028694</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., et al. , A therapy for suppressing canonical and non-canonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response. NCBI Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214482. Deposited 27 September 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11287264</ArticleId><ArticleId IdType="pubmed">39028694</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., et al. , A therapy for suppressing canonical and non-canonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response. Figshare. https://figshare.com/s/13587b74c09c251b3345. Deposited 17 June 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11287264</ArticleId><ArticleId IdType="pubmed">39028694</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibel S. L., et al. , A therapy for suppressing canonical and non-canonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response. DataCite Commons. 10.26180/14073236.v1. Deposited 17 April 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.26180/14073236.v1</ArticleId><ArticleId IdType="pmc">PMC11287264</ArticleId><ArticleId IdType="pubmed">39028694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>